FOI Request FOI 1110-1819

Title
A Phase 1 study of the safety and immune effects of an escalating dose of autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells in patients with metastatic GD2-positive melanoma.
A Phase I/IIa Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With Respiratory Syncytial Virus Lower Respiratory Tract Infection, Consisting of an Open-label Lead-in Part Followed by a Double-blind, Placebo-controlled Part, to Evaluate the Safety, Tolerability and Clinical Activity of ALX-0171, Administered via Inhalation, in Addition to Standard of Care.
A Single Arm, Open-Label Phase 1 Study to Evaluate the Safety and Tolerability of ISC-hoNSC Injected in to the Striatum and Substantia Nigra of Patients with Parkinson's Disease.
A series of Phase 1 clinical trials to examine the safety and efficacy of novel DNA vaccines designed to elicit humoral and cell mediated immunity against hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
A phase I study investigating the safety and tolerability of an infusion of T lymphocytes transduced with an anti-LewisY (LeY) chimeric receptor gene in patients with LeY expressing solid tumours.
A phase I study of CD19 specific chimeric antigen receptor T-cells for therapy of persistent and relapsed B-cell leukaemia and lymphoma post allogeneic stem cell transplantation (The CARTELL study). AND, Co-administration of malignancy and infection specific T-cells after allogeneic stem cell transplant for acute leukaemia with CD34+ selected stem cells (COMITTAL34).
Phase II trial for use of RO7034067 in patients with either Type 1, 2 or 3 Spinal Muscular Atrophy (SMA). The Sponsor has proposed two clinical trials: • BP36055 in patients aged ≥ 1 month and ≤ 7 months with type 1 SMA • BP36056 in patients aged 2 – 25 years with type 2 or 3 SMA
[redacted]